Study on the Relationship Between Peripheral Blood miRNA and Risk and Severity of Alzheimer's Disease
NCT06442852 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2024-06-04
Summary
Alzheimer's Disease, AD is a type of neurofibrillary tangles formed by the deposition of beta amyloid proteins within the nervous system cells and excessive phosphorylation of extracellular Tau proteins, NFTs are the main pathological features of central nervous system degeneration, also known as senile dementia. In addition, synaptic plasticity damage and neuroinflammation also play important roles in the progression of AD. Neurosynapses are the sites where neurons interact with each other in terms of function, and are also crucial for neuronal information transmission and communication. Synapses are the fundamental units in the brain, and synaptic activity can stimulate the maturation of mushroom like dendritic spines and form new synapses, enabling synaptic strength to adapt to changes in the internal and external environment, thereby playing an important role in learning and memory. Previous studies have shown that synaptic activity interruption and synaptic loss can already be detected in the AD brain, especially in the early stages. Multiple studies have shown a higher correlation between synaptic disorders characterized by synaptic loss and decreased synaptic activity and cognitive impairment in Alzheimer's disease compared to age-related plaques and neurofibrillary tangles. Therefore, understanding the potential mechanisms of synaptic disorders will contribute to the development of early treatment strategies for AD. MicroRNAs (miRNAs) are a type of small non coding RNA with a length of approximately 22 nucleotides. Their main function is to silence target genes at the post transcriptional level and inhibit the translation process of their proteins. MiRNAs are involved in many physiological processes and pathological pathways, including development, tumorigenesis, and heart disease. Recently, people have also studied the abnormal regulatory role of miRNAs in AD synaptic disorders. Some miRNAs enriched in the brain, such as miR-124, MiR-132 is abnormally expressed in the AD brain, mediating synaptic plasticity damage. However, most of the miRNAs mentioned above are not directly related to synaptic activity, and their regulation of AD synaptic damage is likely to be a broad-spectrum effect. At present, there are 12 miRNAs closely related to synaptic plasticity that have been identified. By detecting changes in miRNAs closely related to synaptic plasticity in peripheral blood of AD patients and healthy volunteers, and exploring their relationship with the severity of AD lesions, it may provide new directions for early diagnosis of AD. The purpose of this study is to: (1) detect the expression levels of miRNAs closely related to synaptic plasticity in the peripheral blood of healthy volunteers and AD patients, and identify the miRNAs with the greatest differences; (2) Analyze the relationship between the expression levels of the aforementioned miRNAs in the peripheral blood of AD patients and the severity of the disease; (3) Analyze the relationship between the expression levels of the aforementioned miRNAs in the peripheral blood of AD patients and the commonly used neuropsychiatric scale scores. We plan to clarify the changes in peripheral blood miRNAs and their relationship with the severity of AD through case-control studies, in order to provide new directions for early diagnosis of AD.
Conditions
- Alzheimer Disease
- MicroRNAs
Interventions
- OTHER
-
exposure
The observed exposure factor was the expression level of synaptic associated mirna in the serum of patients with Alzheimer's disease and healthy volunteers
Sponsors & Collaborators
-
Jiajie Chen
lead OTHER
Principal Investigators
-
Kai Zheng · Tongji Hospital
Eligibility
- Min Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-04-03
- Primary Completion
- 2026-12-30
- Completion
- 2026-12-30
Countries
- China
Study Locations
More Related Trials
-
Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease
NCT06856681 ·Status: WITHDRAWN ·Phase: NA
-
Cohort Study on Cognitive Decline in Elderly
NCT07093892 ·Status: NOT_YET_RECRUITING
-
Imagery in Early Stages of Dementia
NCT05232526 ·Status: UNKNOWN ·Phase: NA
-
The Revitalize Study in Older Adults at Risk for Alzheimer's Disease
NCT04018092 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Digital Technology Combined With Blood Marker Screening and Diagnosis for Community Populations Based on Classification Theory: an Integrated Study
NCT07286812 ·Status: NOT_YET_RECRUITING
-
The Chinese Familial Alzheimer's Network
NCT03657732 ·Status: RECRUITING
-
Factors Associated With Mortality, Morbidity and Prognosis in Dementia Patients
NCT05052450 ·Status: COMPLETED
-
Cerebrovascular Reactivity in Alzheimer's Disease
NCT03650816 ·Status: COMPLETED
-
Predictive Factors for Initial MMSE Score and Rapid Decline in Alzheimer's Disease Patients
NCT07122856 ·Status: NOT_YET_RECRUITING
-
Monetary Cost of Alzheimer's Disease in China
NCT02694445 ·Status: COMPLETED
-
Predictors of Cognitive Decline in Normal Aging
NCT00094939 ·Status: UNKNOWN
-
Cognitive Decline in AD
NCT03946930 ·Status: RECRUITING
-
Exploring Biomarkers in Age Stratified PUMCH Dementia Cohort
NCT04924361 ·Status: RECRUITING
-
Sensory Support Care for Elderly Patients Suffering From Alzheimer'S-type Neurodegenerative Disease
NCT01819714 ·Status: COMPLETED ·Phase: NA
-
Cognitive Impairment in Ageing People
NCT04360200 ·Status: RECRUITING
-
Personalized Interventions Via Health Portraits in Mild Behavioral Impairment
NCT06416514 ·Status: RECRUITING ·Phase: NA
-
Frailty Outcomes And Risk With Alzheimer's Related Dementia
NCT06570109 ·Status: ENROLLING_BY_INVITATION
-
Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)
NCT05364307 ·Status: COMPLETED
-
Preventing Alzheimer's With Cognitive Training
NCT03848312 ·Status: RECRUITING ·Phase: PHASE3
-
Mortality Risk Prediction Tool in Hospitalized Dementia Patients
NCT05371782 ·Status: COMPLETED
-
Brain NAD in Alzheimer's Disease
NCT07127510 ·Status: RECRUITING
-
A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a Real World Setting
NCT03448445 ·Status: COMPLETED
-
Risk Evaluation and Education for Alzheimer's Disease
NCT00571025 ·Status: COMPLETED ·Phase: NA
-
Multimodal Deep Learning for the Diagnosis and Assessment of Alzheimer's Disease
NCT06081569 ·Status: NOT_YET_RECRUITING
-
China Cognition and Aging Study
NCT03653156 ·Status: RECRUITING